CJC-1295 Ipamorelin Blend Research Peptide (No DAC)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
CJC-1295 Ipamorelin Blend (No DAC) is a laboratory-formulated research peptide blend combining two mechanistically distinct synthetic growth hormone secretagogues, supplied by Nextday Peptides for laboratory and analytical research applications. This CJC-1295 Ipamorelin Blend pairs CJC-1295 No DAC (Modified GRF 1-29), a GHRH receptor agonist activating cAMP/PKA signaling, with Ipamorelin, a selective GHS-R1a agonist activating Gq/PLC-dependent calcium signaling. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Blend Specifications
| Blend Components | CJC-1295 No DAC (Modified GRF 1-29) + Ipamorelin |
| CJC-1295 No DAC | 29 amino acid GHRH analog — GHRHR agonist |
| Ipamorelin | 5 amino acid pentapeptide — GHS-R1a agonist |
| Receptor Targets | GHRHR (CJC-1295) + GHS-R1a (Ipamorelin) |
| Signaling Pathways | cAMP/PKA (CJC) + Gq/PLC calcium (Ipamorelin) |
| Form | Lyophilized powder blend |
| Appearance | White to off-white powder |
| Purity | ≥99% each component (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| CAS — CJC-1295 No DAC | 446036-97-1 |
| CAS — Ipamorelin | 170851-70-4 |
Why Research Laboratories Select This CJC-1295 Ipamorelin Blend
The CJC-1295 Ipamorelin Blend No DAC is one of the most studied dual-secretagogue combinations in current growth hormone axis research. By combining a GHRH receptor agonist with a selective ghrelin receptor agonist, this blend enables laboratories to investigate dual-pathway GH secretagogue signaling, receptor cross-talk, and complementary second messenger pathway interactions in a single experimental system.
- Dual receptor targeting — GHRHR via CJC-1295 No DAC and GHS-R1a via Ipamorelin simultaneously
- Complementary signaling pathways — cAMP/PKA and Gq/PLC calcium pathways studied together
- Each component in the CJC-1295 Ipamorelin Blend independently verified to ≥99% HPLC purity
- No-DAC formulation — shorter-acting pulsatile dynamics versus sustained DAC-based studies
- Ipamorelin component studied for selectivity — minimal cross-reactivity with other pituitary pathways
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
The CJC-1295 Ipamorelin Blend combines two compounds with well-established scientific literature. Teichman et al. (2006) published pharmacokinetic data on CJC-1295 in the Journal of Clinical Endocrinology and Metabolism. Raun et al. (1998) characterized Ipamorelin’s selective GHS-R1a binding in the European Journal of Endocrinology. Bowers et al. (1990) described synergistic effects of GHRH and ghrelin receptor co-activation in Endocrinology. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: PubChem — Ipamorelin | PubChem — CJC-1295
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before cutoff
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized blend at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 14–28 days
- Avoid repeated freeze-thaw cycles to maintain integrity of both components
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is the CJC-1295 Ipamorelin Blend No DAC?
The CJC-1295 Ipamorelin Blend is a laboratory-formulated blend combining CJC-1295 No DAC (Modified GRF 1-29), a GHRH receptor agonist, with Ipamorelin, a selective GHS-R1a agonist. The two peptides target different receptors and activate complementary signaling pathways. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
Why are CJC-1295 and Ipamorelin studied together in a blend?
CJC-1295 No DAC activates GHRH receptors via cAMP/PKA signaling. Ipamorelin activates ghrelin receptors via Gq/PLC-dependent calcium signaling. Because they act on different receptors through different pathways, research has examined their combined effects on dual-pathway GH axis signaling in experimental models.
What is the difference between this blend and the individual peptides?
Individual peptides allow researchers to isolate single receptor pathway effects. The CJC-1295 Ipamorelin Blend allows simultaneous dual-receptor investigation in a single experimental system, useful for studies focused on receptor cross-talk and pathway interaction dynamics.
What purity is your CJC-1295 Ipamorelin Blend?
Each component is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Most orders process same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. This product is for laboratory research use only. It is not approved for human or veterinary use, and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We also carry individual Ipamorelin, Sermorelin, BPC-157, and TB-500. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not evaluated by the FDA • Supplied by Nextday Peptides for laboratory research applications only
